PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
13.37%
Cash & equivalents growing 13.37% while CRVO's declined -7.13%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
13.37%
Below half of CRVO's -7.13%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
12.78%
Below half of CRVO's -7.30%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-7.38%
Below half CRVO's -19.62%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.96%
≥ 1.5x CRVO's -0.54%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
12.46%
Below half of CRVO's -6.23%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-8.08%
Less than half of CRVO's -21.30%. David Dodd sees a more disciplined AP approach or lower volume.
2.29%
Higher Short-Term Debt Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
8.08%
Higher Deferred Revenue (Current) Growth compared to CRVO's zero value, indicating better performance.
-2.29%
Higher Other Current Liabilities Growth compared to CRVO's zero value, indicating worse performance.
-6.99%
Above 1.5x CRVO's -0.59%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-58.38%
Above 1.5x CRVO's -1.95%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
-9.31%
Above 1.5x CRVO's -0.83%. Michael Burry sees a potential leverage warning sign.
10.53%
Higher Common Stock (Book Value) Growth compared to CRVO's zero value, indicating worse performance.
-2.12%
0.5-0.75x CRVO's -3.42%. Martin Whitman is wary of weaker retention or lower profitability.
-7.96%
Higher AOCI Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
13.80%
Below half CRVO's -6.49%. Michael Burry sees potential underperformance in building shareholder capital.
12.46%
Below half CRVO's -6.23%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-16.56%
Similar yoy changes to CRVO's -20.22%. Walter Schloss notes parallel total debt strategies.
-13.63%
Less than half of CRVO's 7.10%. David Dodd sees better deleveraging or stronger cash buildup than competitor.